Search

Press Release: Economic burden of blood disorders in EU is €23 billion

Jul 22 2016 Posted in Press releases

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

2013 & before

2013
EHA-SWG Scientific Meeting on Thrombocytopenia and Disorders of Platelet Function
September 27-29, 2013 | Lisbon, Portugal

EHA-ROHS-RSH Tutorial on Bone Marrow Transplantation
July 5-7, 2013 | Saint Petersburg, Russia

EHA Tutorial on Lymphoma
May 24-26, 2013 | Cape Town, South Africa

EHA-TSH Tutorial on Chronic Myeloproliferative…

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Jun 11 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Chairs and Members

Chair (2020–2025 term)Prof Raúl Córdoba (Spain)

Vice-chairProf Valentín Goede (Germany)

SWG Executive Board
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive…

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).